uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
16 juin 2021 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 16, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Global Clinical Trials Market Analysis Report 2021: Phase III Clinical Trials Dominated the Market with a Share of 53.2% in 2020 - Forecast to 2028
04 juin 2021 07h33 HE
|
Research and Markets
Dublin, June 04, 2021 (GLOBE NEWSWIRE) -- The "Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Study Design (Interventional,...
Neovasc Announces First Patient Enrollment in COSIMA Trial
10 mai 2021 09h05 HE
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, May 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire ‒ Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the first patient has been enrolled...
World Virtual Clinical Trial Service Providers Market 2020-2025, by Type of Therapeutic Area, End-Users, Phase of Development and Key Geographies
27 avr. 2021 08h38 HE
|
Research and Markets
Dublin, April 27, 2021 (GLOBE NEWSWIRE) -- The "Virtual Clinical Trial Service Providers Market by Type of Therapeutic Area, End-Users, Phase of Development (Phase I, Phase II, Phase III and Phase...
Data Science Impacting the Pharmaceutical Industry, 2020 Report: Focus on Clinical Trials - Data Science-driven Patient Selection & FDA Accelerated Data Sharing has Opened Many Opportunities
10 févr. 2021 04h18 HE
|
Research and Markets
Dublin, Feb. 10, 2021 (GLOBE NEWSWIRE) -- The "Data Science Impacting the Pharmaceutical Industry Part II: Clinical Trial Applications" report has been added to ResearchAndMarkets.com's offering. ...
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
19 janv. 2021 08h30 HE
|
Phathom Pharmaceuticals
Topline results expected in second quarter of 2021NDA submission for H. pylori expected in second half of 2021 FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,...
American BriVision Announces Completed Patient Enrollment in Clinical Trial at UCSF for Treatment of Adult ADHD
15 juin 2020 09h00 HE
|
American BriVision Holding Corporation
Patient enrollment has been completed for a Phase II Part I clinical trial at the University of California, San Francisco (UCSF) Medical Center Primary objective of Phase II Part I clinical trial is...
N.M. MEDICAL CANNABIS PROGRAM SEES RECORD PATIENT GROWTH
25 juil. 2017 15h00 HE
|
Ultra Health
Albuquerque, NM, July 25, 2017 (GLOBE NEWSWIRE) -- The New Mexico Medical Cannabis Program’s patient enrollment has seen its fastest growth yet, climbing by 15,357 patients or 53 percent in the...
Achillion Announces That Janssen Has Initiated a Phase 2a Study to Evaluate the Combination of AL-335, Odalasvir (ACH-3102), and Simeprevir for the Treatment of Genotype 1 Chronic HCV
16 oct. 2015 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Oct. 16, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen)...
Phase IV Clinical Trial Teams Identify Top Challenges for Post-Marketing Studies
27 juil. 2011 12h05 HE
|
Cutting Edge Information
PHILADELPHIA, PA and RESEARCH TRIANGLE PARK, NC--(Marketwire - Jul 27, 2011) - Phase IV clinical trial managers face several challenges in maximizing the impact of post-marketing studies, but...